TickerFacts.

Trevi Therapeutics, Inc. (TRVI): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$144.0K
Year ended 2025-12-31
$137.0K
Trailing 12 months to 2026-06-30
+49.6%
3-year compound annual growth
$147.0K2022-12-31: $43.0K2023-12-31: $123.0K2024-12-31: $147.0K2025-12-31: $144.0K$144.0K
2022-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$144.0K-2.0%2026-03-17, From 2025-01-01
2024-12-31$147.0K+19.5%2026-03-17, From 2024-01-01
2023-12-31$123.0K+186.0%2025-03-18, From 2023-01-01
2022-12-31$43.0Kn/a2024-03-20, From 2022-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Trevi Therapeutics, Inc. (TRVI)2025-12-31$144.0K-2.0%
Adicet Bio, Inc. (ACET)2025-12-31$6.38M-1.3%
Foghorn Therapeutics Inc. (FHTX)2025-12-31$3.33M+6.8%
UroGen Pharma Ltd. (URGN)2025-12-31$307.0K-6.7%
Lexicon Pharmaceuticals, Inc. (LXRX)2025-12-31$621.0K+16.3%
Alto Neuroscience, Inc. (ANRO)2024-12-31$502.0K+34.6%
Benitec Biopharma Inc. (BNTC)2026-06-30$58.0K-12.1%
PepGen Inc. (PEPG)2025-12-31$1.40M-6.7%
Puma Biotechnology, Inc. (PBYI)2025-12-31$10.94M-5.1%

Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗